REESE DAVID M 4

4 · AMGEN INC · Filed May 7, 2026

AI-generated summary of this filing

Updated May 8, 2026

Amgen (AMGN) EVP David Reese Receives RSUs and $6.26M Option Grant

What Happened

David M. Reese, EVP & Chief Technology Officer of Amgen (AMGN), was granted equity on 2026-05-05 and had a small tax-withholding disposition on 2026-05-06.
- Grant: 2,912 restricted stock units (RSUs) reported as acquired at $0.00.
- Derivative grant: 19,002 non-qualified stock options (reported as a derivative acquisition) with a strike/ reporting price of $329.59, reported value $6,262,869.
- Tax withholding: 454 shares were disposed on 2026-05-06 at $329.59 to cover tax liability, yielding $149,634.
Filing was submitted on 2026-05-07 (covering the 5/5/2026 transactions).

Key Details

Transaction dates and prices:
- 5/5/2026: RSU grant — 2,912 shares @ $0.00.
- 5/5/2026: Option grant (derivative) — 19,002 shares @ $329.59 (value $6,262,869).
- 5/6/2026: Tax withholding — 454 shares disposed @ $329.59 for $149,634.
Shares owned after transaction: Not specified in the Form 4 excerpts provided.
Relevant footnotes:
- F1: RSUs vest in four equal annual installments (25%/year) beginning 5/5/2027, prorated for months worked in 2026; vested RSUs paid 1:1 in common shares.
- F2: 415 Dividend Equivalents are included in the RSUs and will be paid in shares according to the vesting schedule.
- F3: The 19,002 instruments are non‑qualified stock options that vest in four equal annual installments starting 5/5/2027, prorated for 2026 service.
Filing timeliness: Form filed 5/7/2026 for transactions on 5/5–5/6/2026 — appears timely.

Context

The 19,002‑share entry is an option grant (a derivative award), not an immediate purchase of common stock; vesting begins 5/5/2027.
The 454‑share disposition is a tax‑withholding event (common when RSUs are issued or vest), not an open‑market sale expressing sentiment.
These are routine compensation awards to an executive; they do not alone indicate buy/sell sentiment.

Form 4

Period: 2026-05-05

EVP & Chief Technology Officer

Transactions

Award
Common Stock
[F1]
2026-05-05+2,912→ 43,266 total
Tax Payment
Common Stock
[F2]
2026-05-06$329.59/sh−454$149,634→ 42,812 total
Award
Nqso (Right to Buy)
[F3]
2026-05-05$329.59/sh+19,002$6,262,869→ 19,002 total
Exercise: $329.59From: 2027-05-05Exp: 2036-05-05→ Common Stock (19,002 underlying)

Footnotes (3)

[F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027, subject to proration based on the number of completed months of active employment in 2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
[F2]These shares include 415 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
[F3]These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027, subject to proration based on the number of completed months of active employment in 2026.

Signature

/s/ David M. Reese|2026-05-06

1 file